

Lee M Jampol

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10758946/publications.pdf>

Version: 2024-02-01

134
papers

9,695
citations

46918

47
h-index

40881

93
g-index

134
all docs

134
docs citations

134
times ranked

5557
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized Trial of Photobiomodulation Therapy for Center-Involved Diabetic Macular Edema with Good Visual Acuity (Protocol AE). <i>Ophthalmology Retina</i> , 2022, 6, 298-307.	1.2	15
2	Managing Center-Involved Diabetic Macular Edema With Good Visual Acuity. <i>JAMA Ophthalmology</i> , 2022, 140, 95.	1.4	2
3	PARACENTRAL ACUTE MIDDLE MACULOPATHY IN CENTRAL RETINAL VEIN OCCLUSION COMPLICATING AMYLOID LIGHT-CHAIN AMYLOIDOSIS. <i>Retinal Cases and Brief Reports</i> , 2022, 16, 543-546.	0.3	4
4	Characterization of Choriocapillaris and Choroidal Abnormalities in Alport Syndrome. <i>Translational Vision Science and Technology</i> , 2022, 11, 23.	1.1	3
5	Indolent Nonprogressive Multifocal Choroidal Lymphoid Lesions. <i>Ophthalmology Retina</i> , 2022, 6, 957-962.	1.2	1
6	Spotlight on the DRCR Retina Network's Photobiomodulation for Diabetic Macular Edema Trial. <i>JAMA Ophthalmology</i> , 2022, , .	1.4	1
7	Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. <i>New England Journal of Medicine</i> , 2022, 387, 692-703.	13.9	31
8	CYSTOID MACULAR EDEMA IN THE SETTING OF PRIMARY VITREORETINAL LYMPHOMA. <i>Retinal Cases and Brief Reports</i> , 2021, 15, 104-106.	0.3	4
9	Optical Coherence Tomography Angiography Quality Across Three Multicenter Clinical Studies of Diabetic Retinopathy. <i>Translational Vision Science and Technology</i> , 2021, 10, 2.	1.1	17
10	Effect of Intravitreal Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2021, 139, 701.	1.4	81
11	Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2021, 139, 725-733.	1.4	16
12	Pneumatic Vitreolysis with Perfluoropropane for Vitreomacular Traction with and without Macular Hole. <i>Ophthalmology</i> , 2021, 128, 1592-1603.	2.5	10
13	Photocoagulation of Transudative Type 2 Retinal Arteriovenous Malformation. <i>JAMA Ophthalmology</i> , 2021, 139, 805.	1.4	2
14	COVID-19, COVID-19 Vaccinations, and Subsequent Abnormalities in the Retina. <i>JAMA Ophthalmology</i> , 2021, 139, 1135.	1.4	39
15	The Spectrum of Internal Limiting Membrane Disease in Alport Syndrome. <i>Retina</i> , 2021, Publish Ahead of Print, .	1.0	3
16	A Multiple Evanescent White Dot Syndrome-like Reaction to Concurrent Retinal Insults. <i>Ophthalmology Retina</i> , 2021, 5, 1017-1026.	1.2	18
17	Need for a New Classification of Diabetic Retinopathy. <i>Retina</i> , 2021, 41, 459-460.	1.0	13
18	Best Vitelliform Macular Dystrophy (BVMD) is a phenocopy of North Carolina Macular Dystrophy (NCMD/MCDR1). <i>Ophthalmic Genetics</i> , 2021, , 1-11.	0.5	6

#	ARTICLE	IF	CITATIONS
19	The Bacillary Detachment in Posterior Segment Ocular Diseases. <i>Ophthalmology Retina</i> , 2020, 4, 454-456.	1.2	55
20	ANTI-“VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND RISK OF TRACTION RETINAL DETACHMENT IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY. <i>Retina</i> , 2020, 40, 1021-1028.	1.0	21
21	Classifications of diabetic macular edema. <i>European Journal of Ophthalmology</i> , 2020, 30, 6-7.	0.7	8
22	INDOLENT, NONPROGRESSIVE, MULTIFOCAL CHOROIDDAL LESIONS. <i>Retina</i> , 2020, 40, 1980-1987.	1.0	4
23	Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning. <i>JAMA Ophthalmology</i> , 2020, 138, 945.	1.4	49
24	Optic nerve head reactive retinal astrocytic tumor treated with photodynamic therapy. <i>American Journal of Ophthalmology Case Reports</i> , 2020, 19, 100827.	0.4	1
25	Relapsing Pigment Epithelial Detachment in Central Serous Chorioretinopathy After Dilated Eye Examination. <i>JAMA Ophthalmology</i> , 2020, 138, 1106.	1.4	5
26	OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY FEATURES OF FOCAL CHOROIDDAL EXCAVATION AND THE CHOROIDDAL STROMA VARIATIONS WITH OCCURRENCE OF EXCAVATION. <i>Retina</i> , 2020, 40, 2319-2324.	1.0	9
27	The Role of Optical Coherence Tomography Angiography in Ranibizumab-Treated Choroidal Neovascularization in Choroidal Osteoma. <i>Case Reports in Ophthalmology</i> , 2020, 11, 370-376.	0.3	0
28	The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma. <i>Ophthalmology</i> , 2020, 127, S148-S157.	2.5	18
29	Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity. <i>JAMA Ophthalmology</i> , 2020, 138, 341.	1.4	30
30	Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2020, 138, 285.	1.4	35
31	Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol TExtension Study). <i>Ophthalmology</i> , 2020, 127, 1201-1210.	2.5	87
32	Evaluation and Care of Patients with Diabetic Retinopathy. <i>New England Journal of Medicine</i> , 2020, 382, 1629-1637.	13.9	118
33	Effect of Intravitreal Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2383.	3.8	70
34	Acute Zonal Occult Outer Retinopathy (AZOOR). <i>Retinal Cases and Brief Reports</i> , 2020, Publish Ahead of Print, .	0.3	4
35	Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab. <i>JAMA Ophthalmology</i> , 2019, 137, 977.	1.4	85
36	Diffuse Uveal Melanocytic Proliferation With Primary Vitreoretinal Lymphoma—Reply. <i>JAMA Ophthalmology</i> , 2019, 137, 1466.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Five-Year Cost-effectiveness of Intravitreal Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2019, 137, 1424.	1.4	32
38	The Diabetic Retinopathy Clinical Research Network (DRCR.net) and Its Contributions to the Treatment of Diabetic Retinopathy. <i>Ophthalmic Research</i> , 2019, 62, 225-230.	1.0	54
39	Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-VEGF Vascular Endothelial Growth Factor Therapy. <i>JAMA Ophthalmology</i> , 2019, 137, 382.	1.4	76
40	Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1880.	3.8	184
41	Diffuse Uveal Melanocytic Proliferation With Primary Vitreoretinal Lymphoma. <i>JAMA Ophthalmology</i> , 2019, 137, 834.	1.4	6
42	SEGMENTAL DIFFUSE VASCULAR LEAKAGE. <i>Retinal Cases and Brief Reports</i> , 2019, Publish Ahead of Print, 628-631.	0.3	1
43	PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY. <i>Retina</i> , 2019, 39, 1646-1654.	1.0	15
44	Vertical Hyperreflective Lesions on Optical Coherence Tomography in Vitreoretinal Lymphoma. <i>JAMA Ophthalmology</i> , 2019, 137, 194.	1.4	47
45	Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging With Ultrawide-Field Imaging for Determining Severity of Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2019, 137, 65.	1.4	125
46	Rationale and Application of the Protocol S Anti-VEGF Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy. <i>Ophthalmology</i> , 2019, 126, 87-95.	2.5	79
47	UNUSUAL SEROUS RETINAL DETACHMENT IN A PATIENT WITH WALDENSTROM MACROGLOBULINEMIA: A CASE REPORT. <i>Retinal Cases and Brief Reports</i> , 2019, 13, 1-4.	0.3	5
48	PANRETINAL PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY. <i>Retina</i> , 2019, 39, 69-78.	1.0	7
49	CHARACTERIZATION AND CORRELATION OF JAMPOL DOTS ON ADAPTIVE OPTICS WITH FOVEAL GRANULARITY ON CONVENTIONAL FUNDUS IMAGING. <i>Retina</i> , 2019, 39, 235-246.	1.0	15
50	Association of Retinal Macrovasculature With Venous Malformations of the Brain. <i>JAMA Ophthalmology</i> , 2018, 136, 380.	1.4	1
51	Persistent Macular Thickening Following Intravitreal Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment. <i>JAMA Ophthalmology</i> , 2018, 136, 257.	1.4	218
52	OCT Angiography Imaging in Serpiginous Choroidopathy. <i>Ophthalmology Retina</i> , 2018, 2, 351-359.	1.2	18
53	Solitary retinal hemangioblastoma findings in OCTA pre- and post-laser therapy. <i>American Journal of Ophthalmology Case Reports</i> , 2018, 10, 59-61.	0.4	11
54	Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreal Anti-VEGF Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema. <i>Ophthalmology</i> , 2018, 125, 1054-1063.	2.5	32

#	ARTICLE	IF	CITATIONS
55	CHARACTERIZING PHOTORECEPTOR CHANGES IN ACUTE POSTERIOR MULTIFOCAL PLACOID PIGMENT EPITHELIOPATHY USING ADAPTIVE OPTICS. <i>Retina</i> , 2018, 38, 39-48.	1.0	19
56	Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema. <i>JAMA Ophthalmology</i> , 2018, 136, 29.	1.4	181
57	PERIPAPILLARY PACHYCHOROID SYNDROME. <i>Retina</i> , 2018, 38, 1652-1667.	1.0	104
58	CLINICALLY INVISIBLE RETINAL HEMANGIOBLASTOMAS DETECTED BY SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY AND FLUORESCCEIN ANGIOGRAPHY IN TWINS. <i>Retinal Cases and Brief Reports</i> , 2018, 12, 12-16.	0.3	11
59	CHANGES IN DIABETIC RETINOPATHY SEVERITY WHEN TREATING DIABETIC MACULAR EDEMA WITH RANIBIZUMAB. <i>Retina</i> , 2018, 38, 1896-1904.	1.0	38
60	Reply. <i>Ophthalmology</i> , 2018, 125, e82.	2.5	0
61	Correlation of Central Retinal Thickness and Visual Acuity in Diabetic Macular Edema. <i>JAMA Ophthalmology</i> , 2018, 136, 1215.	1.4	40
62	Statistical Model of Optical Coherence Tomography Angiography Parameters That Correlate With Severity of Diabetic Retinopathy. , 2018, 59, 4292.		72
63	Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy. <i>Ophthalmology</i> , 2018, 125, 1776-1783.	2.5	25
64	Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. , 2018, 59, 1199.		31
65	Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2018, 136, 1138.	1.4	264
66	Importance of Considering the Middle Capillary Plexus on OCT Angiography in Diabetic Retinopathy. , 2018, 59, 2167.		97
67	Early Response to Anti-VEGF and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T. <i>American Journal of Ophthalmology</i> , 2018, 195, 93-100.	1.7	77
68	Reply. <i>Ophthalmology</i> , 2017, 124, e5-e6.	2.5	0
69	Keeping the Name of Acute Posterior Multifocal Placoid Pigment Epitheliopathy. <i>JAMA Ophthalmology</i> , 2017, 135, 186.	1.4	2
70	En Face Optical Coherence Tomography Analysis to Assess the Spectrum of Perivenular Ischemia and Paracentral Acute Middle Maculopathy in Retinal Vein Occlusion. <i>American Journal of Ophthalmology</i> , 2017, 177, 131-138.	1.7	84
71	Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab. <i>Ophthalmology</i> , 2017, 124, 431-439.	2.5	74
72	Cost-effectiveness of Intravitreal Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2017, 135, 576.	1.4	59

#	ARTICLE	IF	CITATIONS
73	Change in Diabetic Retinopathy Through 2 Years. JAMA Ophthalmology, 2017, 135, 558.	1.4	135
74	Interim Safety Data Comparing Ranibizumab With Panretinal Photocoagulation Among Participants With Proliferative Diabetic Retinopathy. JAMA Ophthalmology, 2017, 135, 672.	1.4	12
75	Reply. Ophthalmology, 2017, 124, e26-e27.	2.5	1
76	Reply. Ophthalmology, 2017, 124, e38-e39.	2.5	0
77	Quantifying Microvascular Abnormalities With Increasing Severity of Diabetic Retinopathy Using Optical Coherence Tomography Angiography. , 2017, 58, BIO307.		263
78	Peripapillary retinal splitting visualized on OCT in glaucoma and glaucoma suspect patients. PLoS ONE, 2017, 12, e0182816.	1.1	18
79	Bullous Variant of Central Serous Chorioretinopathy. Ophthalmology, 2016, 123, 1541-1552.	2.5	56
80	Anti-vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema. JAMA Ophthalmology, 2016, 134, 1429.	1.4	44
81	Chorioretinal Lesions in a Case of Melanoma-Associated Retinopathy Treated With Pembrolizumab. JAMA Ophthalmology, 2016, 134, 1184.	1.4	43
82	Elimination of Topical Antibiotics for Intravitreal Injections and the Importance of Using Povidone-Iodine. JAMA Ophthalmology, 2016, 134, 1181.	1.4	31
83	Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial. American Journal of Ophthalmology, 2016, 170, 206-213.	1.7	39
84	Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment. JAMA Ophthalmology, 2016, 134, 888.	1.4	152
85	Zika Virus, Microcephaly, and Ocular Findings—Reply. JAMA Ophthalmology, 2016, 134, 946.	1.4	2
86	Multimodal Imaging and Choroidal Volumetric Changes After Half-fluence PDT in Central Serous Chorioretinopathy. Current Eye Research, 2016, 41, 97-106.	0.7	8
87	Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema. American Journal of Ophthalmology, 2016, 164, 57-68.	1.7	123
88	New associations of classic acute macular neuroretinopathy. British Journal of Ophthalmology, 2016, 100, 389-394.	2.1	73
89	A case of recurrent, self-inflicted handheld laser retinopathy. Journal of AAPOS, 2016, 20, 168-170.	0.2	18
90	Zika Virus Infection and the Eye. JAMA Ophthalmology, 2016, 134, 535.	1.4	56

#	ARTICLE	IF	CITATIONS
91	Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. <i>Ophthalmology</i> , 2016, 123, 1351-1359.	2.5	731
92	Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment. <i>JAMA Ophthalmology</i> , 2016, 134, 278.	1.4	159
93	Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. <i>JAMA Ophthalmology</i> , 2016, 134, 127.	1.4	68
94	MMP19 expression in the human optic nerve. <i>Molecular Vision</i> , 2016, 22, 1429-1436.	1.1	3
95	Reply. <i>Retina</i> , 2015, 35, e68-e69.	1.0	0
96	TOPICAL NEPAFENEC IN EYES WITH NONCENTRAL DIABETIC MACULAR EDEMA. <i>Retina</i> , 2015, 35, 944-956.	1.0	73
97	Differentiation of Diabetic Macular Edema From Pseudophakic Cystoid Macular Edema by Spectral-Domain Optical Coherence Tomography. , 2015, 56, 6724.		61
98	Assessing the Effect of Personalized Diabetes Risk Assessments During Ophthalmologic Visits on Glycemic Control. <i>JAMA Ophthalmology</i> , 2015, 133, 888.	1.4	29
99	Prevention of Hydroxychloroquine-Related Retinal Toxic Effects—Reply. <i>JAMA Ophthalmology</i> , 2015, 133, 492.	1.4	1
100	Panretinal Photocoagulation vs Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2137.	3.8	599
101	Repeated Intravitreal Ranibizumab Injections for Diabetic Macular Edema and the Risk of Sustained Elevation of Intraocular Pressure or the Need for Ocular Hypotensive Treatment. <i>JAMA Ophthalmology</i> , 2015, 133, 589.	1.4	65
102	Association of Diabetic Macular Nonperfusion With Outer Retinal Disruption on Optical Coherence Tomography. <i>JAMA Ophthalmology</i> , 2015, 133, 1036.	1.4	105
103	Comparative Effectiveness Trial for Diabetic Macular Edema. <i>JAMA Ophthalmology</i> , 2015, 133, 983.	1.4	13
104	Enhanced depth imaging optical coherence tomography of congenital cavitory optic disc anomaly (CODA). <i>British Journal of Ophthalmology</i> , 2015, 99, 549-555.	2.1	3
105	Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. <i>New England Journal of Medicine</i> , 2015, 372, 1193-1203.	13.9	1,255
106	Ebola and the Eye. <i>JAMA Ophthalmology</i> , 2015, 133, 1105.	1.4	12
107	Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results. <i>Ophthalmology</i> , 2015, 122, 375-381.	2.5	421
108	Imaging of a Cilioretinal Artery Embolisation. <i>International Journal of Molecular Sciences</i> , 2014, 15, 15734-15740.	1.8	9

#	ARTICLE	IF	CITATIONS
109	Multimodal Imaging in Persistent Placoid Maculopathy. JAMA Ophthalmology, 2014, 132, 38.	1.4	36
110	Revolution to a New Standard Treatment of Diabetic Macular Edema. JAMA - Journal of the American Medical Association, 2014, 311, 2269.	3.8	40
111	Reversible Nyctalopia and Retinopathy in a Patient With Metastatic Cancer Treated With Anti-Heat Shock Protein 90 Therapy. JAMA Ophthalmology, 2014, 132, 899.	1.4	7
112	Acute Zonal Occult Outer Retinopathy. JAMA Ophthalmology, 2014, 132, 1089.	1.4	126
113	Evaluation of Results 1 Year Following Short-term Use of Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy. JAMA Ophthalmology, 2014, 132, 889.	1.4	29
114	Retinal toxicity found in a patient with systemic lupus erythematosus prior to 5 years of treatment with hydroxychloroquine. Rheumatology, 2014, 53, 2001-2001.	0.9	15
115	Melvin L. Rubin, MD (1932-2014). JAMA Ophthalmology, 2014, 132, 788.	1.4	0
116	TRIBUTE TO YANNUZZI. Retina, 2012, 32, S19-S20.	1.0	0
117	Does Laser Still Have a Role in the Management of Retinal Vascular and Neovascular Diseases?. American Journal of Ophthalmology, 2011, 152, 332-339.e1.	1.7	55
118	PHARMACOLOGIC THERAPY OF PSEUDOPHAKIC CYSTOID MACULAR EDEMA. Retina, 2011, 31, 4-12.	1.0	96
119	Nonsteroidal Anti-inflammatory Drugs in Ophthalmology. Survey of Ophthalmology, 2010, 55, 108-133.	1.7	300
120	A Perspective on Commercial Relationships Between Ophthalmology and Industry. JAMA Ophthalmology, 2009, 127, 1194.	2.6	7
121	MULTIPLE SEROUS RETINAL DETACHMENTS AND SUBRETINAL DEPOSITS AS THE PRESENTING SIGNS OF METASTATIC MELANOMA. Retina, 2004, 24, 320-322.	1.0	30
122	White spot syndromes of the retina: a hypothesis based on the common genetic hypothesis of autoimmune/inflammatory disease. American Journal of Ophthalmology, 2003, 135, 376-379.	1.7	182
123	The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. Ophthalmology, 2002, 109, 2197-2206.	2.5	327
124	Nonsteroidal Anti-inflammatory Drugs and Cataract Surgery. JAMA Ophthalmology, 1994, 112, 891.	2.6	27
125	Improvement in Visual Acuity in Chronic Aphakic and Pseudophakic Cystoid Macular Edema After Treatment With Topical 0.5% Ketorolac Tromethamine. American Journal of Ophthalmology, 1991, 112, 514-519.	1.7	149
126	Aphakic Cystoid Macular Edema. JAMA Ophthalmology, 1985, 103, 1134.	2.6	38

#	ARTICLE	IF	CITATIONS
127	Effect of an Ultraviolet-filtering Intraocular Lens on Cystoid Macular Edema. <i>Ophthalmology</i> , 1985, 92, 366-369.	2.5	102
128	Pharmacologic Therapy of Aphakic and Pseudophakic Cystoid Macular Edema. <i>Ophthalmology</i> , 1985, 92, 807-810.	2.5	54
129	Prophylaxis of Pseudophakic Cystoid Macular Edema with Topical Indomethacin. <i>Ophthalmology</i> , 1982, 89, 885-890.	2.5	113
130	Pharmacologic Therapy of Aphakic Cystoid Macular Edema. <i>Ophthalmology</i> , 1982, 89, 891-897.	2.5	71
131	Further studies of the ipsilateral and contralateral responses to topical nitrogen mustard. <i>Experimental Eye Research</i> , 1979, 28, 591-600.	1.2	10
132	Ocular Clinical Findings and Basement Membrane Changes in Goodpasture's Syndrome. <i>American Journal of Ophthalmology</i> , 1975, 79, 452-463.	1.7	87
133	Report of the familial occurrence of systemic lupus erythematosus in male siblings. <i>Arthritis and Rheumatism</i> , 1973, 16, 221-224.	6.7	8
134	Aspirin Prevents the Disruption of the Blood-Aqueous Barrier in the Rabbit Eye. <i>Nature</i> , 1972, 238, 158-159.	13.7	135